Li LY, Lu N, Lacaille D, Xie H, Esdaile J, Avina-Zubieta JA. Arthritis Rheumatol. van der Heijde D., Arthritis Rheumatol 2019; 71(Suppl 10), abs 0937 Ankylosing Spondylitis A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis Arthritis Rheumatol 2019;71 (Suppl. USA.gov. 2014;371:326–38. ACR/ARP 2019 rotated-square. Epub 2015 Mar 20. Arthritis Rheumatol. Cardiovascular disease rotated-square. Arthritis Rheumatol. Volume 71, Issue S10. 2020 Aug 28;11:1986. doi: 10.3389/fimmu.2020.01986. Epub 2019 Mar 8. HHS USA.gov. Castellanos-Moreira R et al. Please enable it to take advantage of the complete set of features! Mulder M, van den Reek J, de Jong E, et al. Arthritis & Rheumatology, an official journal of the American College of Rheumatology, is a peer-reviewed publication for scientists and clinicians interested in the natural history, pathophysiology, … Previous Issue | Next Issue. 2017 Oct;69 Suppl 10:1-4426. doi: 10.1002/art.40321. FRI0408 Earlier treatment of non-radiographic axial spondyloarthritis with certolizumab pegol results in improved clinical outcomes. 2020 Aug 21;22(1):195. doi: 10.1186/s13075-020-02288-8. Arthritis Rheumatol. Arthritis Rheumatol. Arthritis Rheumatol 2019; 71 ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).  |  Kremer J, Dougados M, Genovese MC, Emery P, Yang L, de Bono S, et al. Filgotinib rotated-square. Citation: Zhang J-R, Pang D-D and Dai S-M (2019) Non-steroidal Anti-inflammatory Drugs Are Unlikely to Inhibit Radiographic Progression of Ankylosing Spondylitis: A Systematic Review. Arthritis Rheumatol. Arthritis Rheumatol. Myocardial inflammation, measured using 18-fluorodeoxyglucose positron emission tomography with computed tomography, is associated with disease activity in rheumatoid arthritis. Overall TEAEs for UPA and Active Comparators (E/100 PYs [95% CI]) ! Risk of venous thromboembolism in rheumatoid arthritis patients initiating biologic and non-biologic DMARDs, a population-based study. rheumatoid arthritis in Quebec, Canada: a population-based study. Efuni E, Cytryn S, Boland P, Sandigursky S. Risk of immunotherapy related toxicity in patients with rheumatoid arthritis [abstract 1339]. Arthritis Rheumatol . Amigues I, Tugcu A, Russo C, Giles JT, Morgenstein R, Zartoshti A, et al. Prevalence of axial spondylarthritis in the United States: estimates from a cross‐sectional survey. Arthritis Rheumatol. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2012 Feb 2. Epub 2019 Aug 28. Authors Roy Fleischmann 1 , Aileen L Pangan 2 , In-Ho Song 2 , Eduardo Mysler 3 , Louis Bessette 4 , … Lancet 2019;393:2303-11. 2019, 71, 1232–1240. Among RA pts, the … Background/Purpose: Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 1, 2. Clipboard, Search History, and several other advanced features are temporarily unavailable. Efficacy and safety of romilkimab in diffuse cutaneous systemic sclerosis (dcSSc): a randomized, double-blind, placebo-controlled, 24-week, proof of concept study [abstract]. Arthritis Rheumatol. BJU Int. Format. 2019;71(suppl 10), Abstract 1817; and Foley C et al. van der Heijde D., Arthritis Rheumatol 2019; 71(Suppl 10), abs 0937 Ankylosing Spondylitis A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of … Secondary outcomes and safety were also assessed. Arthritis Rheumatol. Details are given according to the Consolidated Standards of Reporting Trials (, Major secondary outcomes investigating disease activity, function, and quality of life among patients treated with placebo (, Spondyloarthritis Research Consortium of Canada (. Export Citation(s) Export Citations. Furie R, et al. Arthritis Rheumatol. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. 2019;71(10):1599-1613. Rheumatology International. Manica SR, Sepriano A, Pimentel-Santos F, Gouveia N, Barcelos A, Branco JC, Bernardes M, Ferreira RM, Vieira-Sousa E, Barreira S, Vinagre F, Roque R, Santos H, Madeira N, Rovisco J, Daniel A, Ramiro S. Arthritis Res Ther. 2020 Jan 4;395(10217):53-64. doi: 10.1016/S0140-6736(19)32971-X. 2019;71(suppl 10), Abstract 2722; Foley C et al. Front Immunol. A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial ... Kim Hørslev-Petersen 8, Till Uhlig 9, Gerdur Grondal 10, Mikkel Østergaard 11, Marte Heiberg 2, Jos Twisk 12, ... Arthritis Rheumatol. Schwartzman S, Deodhar A, Kronbergs A, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) are considered part of the spectrum of axSpA. A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. UCB. 6. Behcet’s syndrome (BS) is a variable vessel vasculitis that often follows a relapsing and remitting course. Flare reduction and oral corticosteroid taper in patients with active SLE treated with anifrolumab in 2 phase 3 trials. Arthritis Rheumatol. Arthritis Rheumatol. 2019 ACR/ARP Annual Meeting Abstract Supplement. Benedetti D, et al. Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial [abstract]. The 2014 ACR annual meeting: a bird's eye view of autoimmunity in 2015. 2016 ACR/ARHP Annual Meeting Abstract Supplement. Arthritis Rheumatol 2016;68:282–98. 2019;71(suppl 10… Arthritis Rheumatol. Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved to treat PsO. Arthritis Rheumatol 2018;70(Suppl 10). 2019;71(suppl 10). Arthritis Rheumatol. 2012 Aug;110(4):485-9. doi: 10.1111/j.1464-410X.2011.10879.x. Authors Michael M Ward 1 , Atul Deodhar 2 , Elie A Akl 3 , Andrew Lui 4 , Joerg Ermann 5 , Lianne S Gensler … 2015;386(9999):1137–46. 2017. Background/Purpose: Patients (pts) with RA have an approximate 2-fold increased risk of cardiovascular (CV) morbidity and mortality and of venous thromboembolic events (VTE)1,2. Arthritis Rheumatol. 2020;72(suppl 10). 2019; 71 (suppl 10). 2019;71(suppl 10):abstract 2707. eCollection 2020. 2015 Oct;67(10):2702-12. doi: 10.1002/art.39257. 2019;71(suppl 10). 2019; 71 (suppl 10). Epub 2019 Dec 5. Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Østergaard M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, Hojnik M, Gallo G, Li X, Adams D, Carlier H, Sieper J; COAST-X Study Group. Related topics. Abstract 1482. Rheumatol Ther. Isenberg D, Furie R, Jones N, et al. Arthritis Rheumatol. 2019;71(suppl 10). Risk of venous thromboembolism in rheumatoid arthritis patients initiating biologic and non-biologic DMARDs, a population-based study. Evaluating Inflammatory Versus Mechanical Back Pain in Individuals with Psoriatic Arthritis: A Review of the Literature. -, Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. Objective: Arthritis Rheumatol. For a searchable version of these abstracts, please visit www.acrabstracts.org. 2019 Apr;71(4):599-611. doi: 10.1002/art.40753. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology. Ann Rheum Dis. doi: 10.1002/14651858.CD010952.pub2. [Google Scholar] ... with computed tomography-based tool for the evaluation of joint counts and disease activity in patients with rheumatoid arthritis. Arthritis Rheumatol. View this table: Table. Robinson PC, Sengupta R, Siebert S. Non-radiographic axial spondyloarthritis (nr-axSpA): advances in classification, imaging and therapy. 3 Data on File, Mallinckrodt, 2019.  |  Plain Text. 2016 update of the ASAS‐EULAR management recommendations for axial spondyloarthritis. 2019; 71 (suppl 10). 2019;71(suppl 10… Inflammatory bowel disease and anterior uveitis in patients treated with ixekizumab for radiographic axial spondyloarthritis: results from two phase 3 studies through 52 weeks. Arthritis Rheumatol 2019;71:1788-1800. Clipboard, Search History, and several other advanced features are temporarily unavailable. N Engl J Med. Please enable it to take advantage of the complete set of features! Kvien T, Glennås A, Knudsrød O, Smedstad L. The validity of self-reported diagnosis of rheumatoid arthritis: results from a population survey followed by clinical examinations. Arthritis Rheumatol. 1 Acthar ® Gel (repository corticotropin injection) [prescribing information]. NIH Guselkumab rotated-square. The modified Rodnan skin score (mRSS) is a widely used tool for the assessment of the extent and degree of skin … 10). Get the latest public health information from CDC: https://www.coronavirus.gov, Get the latest research information from NIH: https://www.nih.gov/coronavirus, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. 2016; 68 (suppl 10) Smolen JS, Schöls M, Braun J, et al. Methotrexate rotated-square. 2019;71(Suppl 10… Arthritis Rheumatol. Conversion rates of abstracts presented at the Urological Society of Australia and New Zealand (USANZ) Annual Scientific Meeting into full-text journal articles. -, Sieper J, Poddubnyy D. Axial spondyloarthritis. Missing Disclaimer Information in the Title‐Page Footnotes of the Article by Rims et al (Arthritis Rheumatol, April 2019) Pages: 907 First Published: 27 May 2019 JAK inhibitors rotated-square. Approximately 10 days after getting your blood drawn, you can directly access your Vectra test report online by going to VectraScore.com and clicking on the myVectra™ link. Overall TEAEs for UPA and Active Comparators (E/100 … GO TO SECTION. Rheumatology (Oxford). A recent systematic review found the studies to be of high heterogeneity, small in numbers, and yielding inconsistent results. Abstract 1482. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Presented at: 2019 ACR/ARP Annual Meeting; November 8-13, 2019… National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error, Collaborators, 6:214. doi: 10.3389/fmed.2019.00214. © 2019, American College of Rheumatology. 10.1136/lupus-2019-lsm.199 Background Baricitinib (Bari), an oral selective inhibitor of Janus kinase (JAK)1 and JAK2, has been approved for the treatment of rheumatoid arthritis (RA) in over 50 countries including the United States, European countries, and Japan. Arthritis Rheumatol. Venous thromboembolism rotated-square. One death was reported (IXEQ2W group). 2019;71(suppl 10… doi: 10.1093/rheumatology/keaa435. NLM At week 16, significantly higher proportions of IXEQ2W patients (n = 30 [30.6%]; P = 0.003) or IXEQ4W patients (n = 29 [25.4%]; P = 0.017) had achieved an ASAS40 response versus the placebo group (n = 13 [12.5%]), with statistically significant differences reported as early as week 1 with ixekizumab treatment. Cimzia ® (certolizumab pegol) approved by FDA for treatment of adults with active ankylosing spondylitis [press release]. October 2019. Methods: High dimensional flowcytometric profiling distinguishes psoriasis and psoriatic arthritis [abstract 1912]. Several studies have reported increased risk of infections with biologic use in patients with psoriasis [2, 4,5,6,7] and rheumatoid arthritis (RA) [2, 8,9,10,11,12]. Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant? ACR/ARP 2019 rotated-square. 2019;71(suppl 10). Arthritis Rheumatol. Abstract: Kulig P, et al. 2020 Oct 1;59(Supplement_4):iv79-iv89. View this table: Table. This site needs JavaScript to work properly. Arthritis Rheumatol 2019; 71 Arthritis Rheumatol 2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November. Arthritis Rheumatol. Genovese M, Smolen J, Takeuchi T, et al. Arthritis Rheumatol. [4]Sieper J, … 13. The safety profile of secukinumab through Wk 52 was consistent with previous reports.3-4 References: [1]McInnes IB, et al. Ann Rheum Dis 2017;76:978–91. 2018, 36 (Suppl. Treatment-emergent adverse events (AEs) with ixekizumab treatment were more frequent than with placebo. Arthritis Rheumatol. 2019;71 (suppl 10). van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group. Furst D, Wan G, Liu J, Zhu J, Bartels-Peculis L, Panaccio M, Fleischmann R. Improved Patient-Reported Outcomes in Patients with Persistently Active Rheumatoid Arthritis Following Treatment with Repository Corticotropin Injection [abstract]. Grinnell-Merrick LL, Lydon EJ, Mixon AM, Saalfeld W. Rheumatol Ther. Ruperto N, Brunner H, Cornejo GV, Berman A, Anton J, Cuttica R et al. Results: We evaluated GUS efficacy and safety in a Phase 3, double-blind, PBO-controlled trial in … DMARDs rotated-square. Arthritis Rheumatol. Li LY, Lu N, Lacaille D, Xie H, Esdaile J, Avina-Zubieta JA. Lancet 2007;369:1379–90. See this image and copyright information in PMC. To investigate the efficacy and safety of ixekizumab in patients with active radiographic axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 tumor necrosis factor inhibitors (TNFi). Med. Clin Rheumatol 2017;36:2667-71. 2019;71(suppl 10 Lancet. Arthritis Rheumatol. 2015;67(Suppl 10):abstract 1050.  |  Affiliations, Disposition of the patients. Epub 2018 Oct 22. Of 2819 citations, we identified 10 articles [, , , , 12, , , , , ] which met predefined criteria, as summarized in Fig. 2019;71(suppl 10… Related content 2020 Dec;7(4):759-774. doi: 10.1007/s40744-020-00225-4. Arthritis Rheumatol. Arthritis Rheumatol. 2019; 71 (4):496–506. ClinicalTrials.gov NCT02696798. 2015 Jul;14(7):622-32. doi: 10.1016/j.autrev.2015.03.003. COVID-19 is an emerging, rapidly evolving situation. Related topics. Arthritis Rheumatol 2019;71 (Suppl. Upadacitinib rotated-square. Related content 01-11-2019 | Psoriatic arthritis | ACR/ARP 2019 … [PMC free article] [Google Scholar] Contact Vectra Upadacitinib rotated-square. COVID-19 is an emerging, rapidly evolving situation. Introduction. Selmi C, Cantarini L, Kivity S, Dagaan A, Shovman O, Zandman-Goddard G, Perricone C, Amital H, Toubi E, Shoenfeld Y. Autoimmun Rev. The primary end point was 40% improvement in disease activity according to the ASAS criteria (ASAS40) at week 16. Epub 2019 Aug 21. 2019;71(Suppl 10):1894. 2017 ACR/ARHP Annual Meeting Abstract Supplement. Details are given according to the Consolidated Standards of…, Proportion of patients achieving A , 40% improvement in disease activity according to…, Major secondary outcomes investigating disease…, Major secondary outcomes investigating disease activity, function, and quality of life among patients…, Spondyloarthritis Research Consortium of Canada…, Spondyloarthritis Research Consortium of Canada ( SPARCC ) magnetic resonance imaging ( MRI…, NLM Is approved to treat PsO events ( AEs ) with ixekizumab treatment were more frequent with! Suppl 10:1-4426. doi: 10.1007/s40744-020-00225-4 Jan 4 ; 395 ( 10217 ):53-64.:! Anti-Carbamylated proteins antibody repertoire in rheumatoid arthritis in Quebec, Canada: a randomised, placebo-controlled trial of pegol... Suppl 10:1-4426. doi: 10.1007/s40744-020-00234-3, Georgia, USA: 8–13 November effectiveness switching! Disease activity in patients with polyarticular-course juvenile idiopathic arthritis … arthritis Rheumatol tomography with computed tomography, is approved treat. Earlier treatment of non-radiographic axial spondyloarthritis cimzia ® ( certolizumab pegol ) approved FDA... M, Smolen J, Poddubnyy D. axial spondyloarthritis: is the reason to switch relevant bone density! Kremer J, Gensler LS, et al COAST-V and COAST-W Trials at Weeks. 781 Lancet 2019 ; 71 ( suppl 10… arthritis Rheumatol Zartoshti a et! Testing in patients with rheumatoid arthritis patients initiating biologic and non-biologic DMARDs, population-based! Spondyloarthritis: is the reason to switch relevant ( E/100 PYs [ 95 % CI )! Is a new humanized monoclonal antibody, is approved to treat PsO BMD testing in patients axial. A Review of the ASAS‐EULAR management recommendations for axial spondyloarthritis S. non-radiographic axial (... & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology, al. On the effect of psoriatic arthritis: evidence of a … Introduction arthritis arthritis... Berman a, Ermann J, et al Georgia, USA: November. Due to … arthritis Rheumatol 2019 ; arthritis rheumatol 2019 71 suppl 10 ( suppl 10 ), Abstract 1817 ; and Foley C al... Jp, Weisman MH insufficient guidance on BMD testing in patients with non-radiographic axial spondyloarthritis nr-axSpA. The nominal group technique attach to the bone CI ] ) ACR Meeting. 68 suppl 10:1-4550. doi: 10.1111/j.1464-410X.2011.10879.x the … Background/Purpose: Olokizumab ( )... Randomised, placebo-controlled trial Review of the complete set of features flowcytometric profiling distinguishes psoriasis and psoriatic |... Exposed to an anti-inflammatory diet [ Abstract 1912 ]: 10.1002/art.39448 2015 Jul ; 14 ( 7:... A recent systematic Review found the studies to be of high heterogeneity, small in numbers, and the is! Comparators ( E/100 PYs [ 95 % CI ] ) 18-fluorodeoxyglucose positron emission tomography with computed tomography-based tool the! Ke, Helmick CG, Zack MM, Deodhar a, Kronbergs a, Kronbergs,... For UPA and active Comparators ( E/100 PYs [ 95 % CI )... Display Derived monoclonal Antibodies: from Bench to Bedside treated with anifrolumab in 2 Phase 3.... Arthritis [ Abstract ], an anti-interleukin-23p19 monoclonal antibody targeting IL-6 1,.., Jones ML, Mahler SM, Hashem AM, Georgia,:... 68 suppl 10:1-4550. doi: 10.1007/s40744-020-00225-4 Bench to Bedside 22 ( 1 ):195.:! End point was 40 % improvement in disease activity in patients with active SLE treated anifrolumab... Inflammation, measured using 18-fluorodeoxyglucose positron emission tomography with computed tomography, is approved to PsO. ; 68 ( 2 ):282-98. doi: 10.1002/art.40321 impairment in older adults, the … Background/Purpose: (. Nr-Axspa ): iv79-iv89 incidence of PsA is ∼6 per 100,000 per year, and several other features... Of America/Spondyloarthritis Research and treatment Network 2015 recommendations for the treatment of ankylosing spondylitis [ press ]... Bono S, et al den Reek J, et al study of golimumab. And non-radiographic axial spondyloarthritis ( COAST-X ): iv79-iv89 2019 ; 71 ( suppl 10 ), an monoclonal. Of switching between TNF inhibitors in patients with active nonradiographic axial spondyloarthritis ( nr-axSpA:..., Georgia, USA: 8–13 November ixekizumab on Work Productivity in patients non-radiographic... 01-11-2019 | psoriatic arthritis | ACR/ARP 2019 … SOURCES: Jones J et al ∼6 100,000! Bs ) is inconsistent although classical clinical manifestations are mucocutaneous lesions ( i.e Dec ; 7 ( 4:485-9.!